Global Cancer Diagnostics Market By Product, By Application, By End User, By Region: Segmental Insights, Trends & Forecast, 2023 – 2031

  • Industry: Healthcare
  • Report ID: TNR-110-989
  • Number of Pages: 420
  • Table/Charts : Yes
  • November, 2023
  • Base Year : 2024
  • No. of Companies : 9+
  • No. of Countries : 29
  • Views : 10072
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Global Cancer Diagnostics Market Was Worth US$ 18.41 Billion in 2022, Estimated to Gain CAGR of 12.0% During 2023-2031.

Cancer diagnostics involves identifying and determining the presence, type, and stage of cancer in a patient’s body. It employs various techniques such as imaging, biopsies, and blood tests to detect abnormalities at cellular and molecular levels. Accurate diagnostics are crucial for effective treatment planning and monitoring the progression of the disease.

Consumables are dominating the global cancer diagnostics market within the product category. The consistent demand for reagents, antibodies, and test kits contributes to their dominance. A study published in the journal “Cancer Epidemiology, Biomarkers & Prevention” highlighted the substantial usage of consumables in cancer screening, diagnosis, and monitoring, solidifying their dominant market position.

Global Cancer Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2031

COVID-19 Impact Analysis on Global Cancer Diagnostics Market

Before the pandemic, the cancer diagnostics market was on a trajectory of steady growth. Innovations in imaging technologies and molecular diagnostics were enhancing early detection and precision treatments, fostering market expansion. The COVID-19 pandemic brought significant shifts to the cancer diagnostics market. Delayed screenings and disrupted healthcare services impacted diagnosis rates. However, the crisis highlighted the importance of resilient diagnostics. Telemedicine adoption and advancements in at-home testing gained prominence, influencing the market’s direction towards more adaptable and patient-centric solutions.

A key driver in the cancer diagnostics market is the growing emphasis on early detection. The American Cancer Society reported that early diagnosis improves survival rates and treatment outcomes. Innovations like liquid biopsies offer non-invasive methods for detecting cancer-associated biomarkers. A study published in “Cancer Epidemiology, Biomarkers & Prevention” highlighted the potential of such approaches. This driver reflects the industry’s commitment to enhancing patient prognosis by detecting cancers at their nascent stages, guiding timely interventions. The substantial costs associated with advanced cancer diagnostic techniques pose a significant restraint. Expensive instruments, specialized training, and complex procedures contribute to the financial burden. A study in the journal “JAMA Oncology” highlighted the economic challenges patients face due to high diagnostic costs. This restraint can hinder access to cutting-edge diagnostics, impacting timely diagnosis and care.

Breast cancer diagnostics is dominating the global cancer diagnostics market within the application category in 2022. Breast cancer accounts for a significant portion of cancer cases, with a substantial focus on early detection. The American Cancer Society notes that mammography screenings have contributed to reduced mortality rates, underscoring the dominance of breast cancer diagnostics.

North America accounted for ~45.8% of the global cancer diagnostics market in 2022. It boasts advanced healthcare infrastructure and proactive screening programs. According to the American Cancer Society, North America has among the highest cancer screening rates globally, indicating its dominant position in diagnostics.

Competitive Landscape

A few of the players operating in the global cancer diagnostics market are

  • Abbott
  • BD
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare
  • Hologic, Inc.
  • Koninklijke Philips N.V.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Other Industry Participants

Global Cancer Diagnostics Market Report Coverage

Report Specifications Details
Market Revenue in 2022 US$ 18.41 Billion
Market Size Forecast by 2031 US$ 51.51 Billion
Growth Rate (CAGR) 12%
Historic Data 2015 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Product, By Application, By End User
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Other Industry Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808-703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

 

Global Cancer Diagnostics Market:

By Product

  • Consumables
    • Antibodies
    • Kits & Reagents
    • Probes
    • Other Consumables
  • Instruments
    • Pathology-Based Instruments
      • Slide Staining Systems
      • Tissue Processing Systems
      • NGS Instruments
      • Cell Processors
      • PCR Instruments
      • Microarrays
      • Other Pathology-Based Instruments
    • Imaging Instruments
      • CT Systems
      • MRI Systems
      • Ultrasound Systems
      • Mammography Systems
      • Nuclear Imaging Systems
    • Biopsy Instruments

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Coverage and Deliverables: 

Common

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2015 - 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Cancer Diagnostics Market
6.Market Synopsis: Cancer Diagnostics Market
7.Cancer Diagnostics Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in Cancer Diagnostics Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Cancer Diagnostics Market
7.6.Porter’s Five Force Analysis
7.7.Impact of Covid-19 on Cancer Diagnostics Market
7.8.PESTEL Analysis
8.Global Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
8.1.Overview
8.1.1.Global Cancer Diagnostics Market Revenue (US$ Mn)
8.2.Global Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
8.2.1.Consumables (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Antibodies, Kits and Reagents, Probes, Other Consumables)
8.2.1.1.Antibodies
8.2.1.2.Kits and Reagents
8.2.1.3.Probes
8.2.1.4.Other Consumables
8.2.2.Instruments (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Pathology-Based Instruments, Imaging Instruments, Biopsy Instruments)
8.2.2.1.Pathology-Based Instruments
8.2.2.1.1.Slide Staining Systems
8.2.2.1.2.Tissue Processing Systems
8.2.2.1.3.NGS Instruments
8.2.2.1.4.Cell Processors
8.2.2.1.5.PCR Instruments
8.2.2.1.6.Microarrays
8.2.2.1.7.Other Pathology-Based Instruments
8.2.2.2.Imaging Instruments
8.2.2.2.1.CT Systems
8.2.2.2.2.MRI Systems
8.2.2.2.3.Ultrasound Systems
8.2.2.2.4.Mammography Systems
8.2.2.2.5.Nuclear Imaging Systems
8.2.2.3.Biopsy Instruments
8.3.Key Segment for Channeling Investments
8.3.1.By Products
9.Global Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
9.1.Overview
9.2.Global Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1.Breast Cancer
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2015 - 2022
9.2.1.3.Market Forecast, 2023 - 2031
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2015 - 2022
9.2.1.5.1.2.Market Forecast, 2023 - 2031
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2015 - 2022
9.2.1.5.2.2.Market Forecast, 2023 - 2031
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2015 - 2022
9.2.1.5.3.2.Market Forecast, 2023 - 2031
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2015 - 2022
9.2.1.5.4.2.Market Forecast, 2023 - 2031
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2015 - 2022
9.2.1.5.5.2.Market Forecast, 2023 - 2031
9.2.2.Colorectal Cancer
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2015 - 2022
9.2.2.3.Market Forecast, 2023 - 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2015 - 2022
9.2.2.5.1.2.Market Forecast, 2023 - 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2015 - 2022
9.2.2.5.2.2.Market Forecast, 2023 - 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2015 - 2022
9.2.2.5.3.2.Market Forecast, 2023 - 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2015 - 2022
9.2.2.5.4.2.Market Forecast, 2023 - 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2015 - 2022
9.2.2.5.5.2.Market Forecast, 2023 - 2031
9.2.3.Cervical Cancer
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2015 - 2022
9.2.3.3.Market Forecast, 2023 - 2031
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2015 - 2022
9.2.3.5.1.2.Market Forecast, 2023 - 2031
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2015 - 2022
9.2.3.5.2.2.Market Forecast, 2023 - 2031
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2015 - 2022
9.2.3.5.3.2.Market Forecast, 2023 - 2031
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2015 - 2022
9.2.3.5.4.2.Market Forecast, 2023 - 2031
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2015 - 2022
9.2.3.5.5.2.Market Forecast, 2023 - 2031
9.2.4.Lung Cancer
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2015 - 2022
9.2.4.3.Market Forecast, 2023 - 2031
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2015 - 2022
9.2.4.5.1.2.Market Forecast, 2023 - 2031
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2015 - 2022
9.2.4.5.2.2.Market Forecast, 2023 - 2031
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2015 - 2022
9.2.4.5.3.2.Market Forecast, 2023 - 2031
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2015 - 2022
9.2.4.5.4.2.Market Forecast, 2023 - 2031
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2015 - 2022
9.2.4.5.5.2.Market Forecast, 2023 - 2031
9.2.5.Prostate Cancer
9.2.5.1.Definition
9.2.5.2.Market Estimation and Penetration, 2015 - 2022
9.2.5.3.Market Forecast, 2023 - 2031
9.2.5.4.Compound Annual Growth Rate (CAGR)
9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2015 - 2022
9.2.5.5.1.2.Market Forecast, 2023 - 2031
9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2015 - 2022
9.2.5.5.2.2.Market Forecast, 2023 - 2031
9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2015 - 2022
9.2.5.5.3.2.Market Forecast, 2023 - 2031
9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2015 - 2022
9.2.5.5.4.2.Market Forecast, 2023 - 2031
9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2015 - 2022
9.2.5.5.5.2.Market Forecast, 2023 - 2031
9.2.6.Skin Cancer
9.2.6.1.Definition
9.2.6.2.Market Estimation and Penetration, 2015 - 2022
9.2.6.3.Market Forecast, 2023 - 2031
9.2.6.4.Compound Annual Growth Rate (CAGR)
9.2.6.5.Regional Bifurcation
9.2.6.5.1.North America
9.2.6.5.1.1.Market Estimation, 2015 - 2022
9.2.6.5.1.2.Market Forecast, 2023 - 2031
9.2.6.5.2.Europe
9.2.6.5.2.1.Market Estimation, 2015 - 2022
9.2.6.5.2.2.Market Forecast, 2023 - 2031
9.2.6.5.3.Asia Pacific
9.2.6.5.3.1.Market Estimation, 2015 - 2022
9.2.6.5.3.2.Market Forecast, 2023 - 2031
9.2.6.5.4.Middle East and Africa
9.2.6.5.4.1.Market Estimation, 2015 - 2022
9.2.6.5.4.2.Market Forecast, 2023 - 2031
9.2.6.5.5.Latin America
9.2.6.5.5.1.Market Estimation, 2015 - 2022
9.2.6.5.5.2.Market Forecast, 2023 - 2031
9.2.7.Blood Cancer
9.2.7.1.Definition
9.2.7.2.Market Estimation and Penetration, 2015 - 2022
9.2.7.3.Market Forecast, 2023 - 2031
9.2.7.4.Compound Annual Growth Rate (CAGR)
9.2.7.5.Regional Bifurcation
9.2.7.5.1.North America
9.2.7.5.1.1.Market Estimation, 2015 - 2022
9.2.7.5.1.2.Market Forecast, 2023 - 2031
9.2.7.5.2.Europe
9.2.7.5.2.1.Market Estimation, 2015 - 2022
9.2.7.5.2.2.Market Forecast, 2023 - 2031
9.2.7.5.3.Asia Pacific
9.2.7.5.3.1.Market Estimation, 2015 - 2022
9.2.7.5.3.2.Market Forecast, 2023 - 2031
9.2.7.5.4.Middle East and Africa
9.2.7.5.4.1.Market Estimation, 2015 - 2022
9.2.7.5.4.2.Market Forecast, 2023 - 2031
9.2.7.5.5.Latin America
9.2.7.5.5.1.Market Estimation, 2015 - 2022
9.2.7.5.5.2.Market Forecast, 2023 - 2031
9.2.8.Kidney Cancer
9.2.8.1.Definition
9.2.8.2.Market Estimation and Penetration, 2015 - 2022
9.2.8.3.Market Forecast, 2023 - 2031
9.2.8.4.Compound Annual Growth Rate (CAGR)
9.2.8.5.Regional Bifurcation
9.2.8.5.1.North America
9.2.8.5.1.1.Market Estimation, 2015 - 2022
9.2.8.5.1.2.Market Forecast, 2023 - 2031
9.2.8.5.2.Europe
9.2.8.5.2.1.Market Estimation, 2015 - 2022
9.2.8.5.2.2.Market Forecast, 2023 - 2031
9.2.8.5.3.Asia Pacific
9.2.8.5.3.1.Market Estimation, 2015 - 2022
9.2.8.5.3.2.Market Forecast, 2023 - 2031
9.2.8.5.4.Middle East and Africa
9.2.8.5.4.1.Market Estimation, 2015 - 2022
9.2.8.5.4.2.Market Forecast, 2023 - 2031
9.2.8.5.5.Latin America
9.2.8.5.5.1.Market Estimation, 2015 - 2022
9.2.8.5.5.2.Market Forecast, 2023 - 2031
9.2.9.Liver Cancer
9.2.9.1.Definition
9.2.9.2.Market Estimation and Penetration, 2015 - 2022
9.2.9.3.Market Forecast, 2023 - 2031
9.2.9.4.Compound Annual Growth Rate (CAGR)
9.2.9.5.Regional Bifurcation
9.2.9.5.1.North America
9.2.9.5.1.1.Market Estimation, 2015 - 2022
9.2.9.5.1.2.Market Forecast, 2023 - 2031
9.2.9.5.2.Europe
9.2.9.5.2.1.Market Estimation, 2015 - 2022
9.2.9.5.2.2.Market Forecast, 2023 - 2031
9.2.9.5.3.Asia Pacific
9.2.9.5.3.1.Market Estimation, 2015 - 2022
9.2.9.5.3.2.Market Forecast, 2023 - 2031
9.2.9.5.4.Middle East and Africa
9.2.9.5.4.1.Market Estimation, 2015 - 2022
9.2.9.5.4.2.Market Forecast, 2023 - 2031
9.2.9.5.5.Latin America
9.2.9.5.5.1.Market Estimation, 2015 - 2022
9.2.9.5.5.2.Market Forecast, 2023 - 2031
9.2.10.Pancreatic Cancer
9.2.10.1.Definition
9.2.10.2.Market Estimation and Penetration, 2015 - 2022
9.2.10.3.Market Forecast, 2023 - 2031
9.2.10.4.Compound Annual Growth Rate (CAGR)
9.2.10.5.Regional Bifurcation
9.2.10.5.1.North America
9.2.10.5.1.1.Market Estimation, 2015 - 2022
9.2.10.5.1.2.Market Forecast, 2023 - 2031
9.2.10.5.2.Europe
9.2.10.5.2.1.Market Estimation, 2015 - 2022
9.2.10.5.2.2.Market Forecast, 2023 - 2031
9.2.10.5.3.Asia Pacific
9.2.10.5.3.1.Market Estimation, 2015 - 2022
9.2.10.5.3.2.Market Forecast, 2023 - 2031
9.2.10.5.4.Middle East and Africa
9.2.10.5.4.1.Market Estimation, 2015 - 2022
9.2.10.5.4.2.Market Forecast, 2023 - 2031
9.2.10.5.5.Latin America
9.2.10.5.5.1.Market Estimation, 2015 - 2022
9.2.10.5.5.2.Market Forecast, 2023 - 2031
9.2.11.Others
9.2.11.1.Definition
9.2.11.2.Market Estimation and Penetration, 2015 - 2022
9.2.11.3.Market Forecast, 2023 - 2031
9.2.11.4.Compound Annual Growth Rate (CAGR)
9.2.11.5.Regional Bifurcation
9.2.11.5.1.North America
9.2.11.5.1.1.Market Estimation, 2015 - 2022
9.2.11.5.1.2.Market Forecast, 2023 - 2031
9.2.11.5.2.Europe
9.2.11.5.2.1.Market Estimation, 2015 - 2022
9.2.11.5.2.2.Market Forecast, 2023 - 2031
9.2.11.5.3.Asia Pacific
9.2.11.5.3.1.Market Estimation, 2015 - 2022
9.2.11.5.3.2.Market Forecast, 2023 - 2031
9.2.11.5.4.Middle East and Africa
9.2.11.5.4.1.Market Estimation, 2015 - 2022
9.2.11.5.4.2.Market Forecast, 2023 - 2031
9.2.11.5.5.Latin America
9.2.11.5.5.1.Market Estimation, 2015 - 2022
9.2.11.5.5.2.Market Forecast, 2023 - 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Application
10.Global Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
10.1.Overview
10.2.Global Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
10.2.1.Hospitals
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2015 - 2022
10.2.1.3.Market Forecast, 2023 - 2031
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2015 - 2022
10.2.1.5.1.2.Market Forecast, 2023 - 2031
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2015 - 2022
10.2.1.5.2.2.Market Forecast, 2023 - 2031
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2015 - 2022
10.2.1.5.3.2.Market Forecast, 2023 - 2031
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2015 - 2022
10.2.1.5.4.2.Market Forecast, 2023 - 2031
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2015 - 2022
10.2.1.5.5.2.Market Forecast, 2023 - 2031
10.2.2.Diagnostic Laboratories
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2015 - 2022
10.2.2.3.Market Forecast, 2023 - 2031
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2015 - 2022
10.2.2.5.1.2.Market Forecast, 2023 - 2031
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2015 - 2022
10.2.2.5.2.2.Market Forecast, 2023 - 2031
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2015 - 2022
10.2.2.5.3.2.Market Forecast, 2023 - 2031
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2015 - 2022
10.2.2.5.4.2.Market Forecast, 2023 - 2031
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2015 - 2022
10.2.2.5.5.2.Market Forecast, 2023 - 2031
10.2.3.Research Institutes
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2015 - 2022
10.2.3.3.Market Forecast, 2023 - 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2015 - 2022
10.2.3.5.1.2.Market Forecast, 2023 - 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2015 - 2022
10.2.3.5.2.2.Market Forecast, 2023 - 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2015 - 2022
10.2.3.5.3.2.Market Forecast, 2023 - 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2015 - 2022
10.2.3.5.4.2.Market Forecast, 2023 - 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2015 - 2022
10.2.3.5.5.2.Market Forecast, 2023 - 2031
10.2.4.Others
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2015 - 2022
10.2.4.3.Market Forecast, 2023 - 2031
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2015 - 2022
10.2.4.5.1.2.Market Forecast, 2023 - 2031
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2015 - 2022
10.2.4.5.2.2.Market Forecast, 2023 - 2031
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2015 - 2022
10.2.4.5.3.2.Market Forecast, 2023 - 2031
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2015 - 2022
10.2.4.5.4.2.Market Forecast, 2023 - 2031
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2015 - 2022
10.2.4.5.5.2.Market Forecast, 2023 - 2031
10.3.Key Segment for Channeling Investments
10.3.1.By End User
11.North America Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
11.1.Overview
11.1.1.North America Cancer Diagnostics Market Revenue (US$ Mn)
11.2.North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
11.2.1.Consumables
11.2.1.1.Antibodies
11.2.1.2.Kits and Reagents
11.2.1.3.Probes
11.2.1.4.Other Consumables
11.2.2.Instruments
11.2.2.1.Pathology-Based Instruments
11.2.2.1.1.Slide Staining Systems
11.2.2.1.2.Tissue Processing Systems
11.2.2.1.3.NGS Instruments
11.2.2.1.4.Cell Processors
11.2.2.1.5.PCR Instruments
11.2.2.1.6.Microarrays
11.2.2.1.7.Other Pathology-Based Instruments
11.2.2.2.Imaging Instruments
11.2.2.2.1.CT Systems
11.2.2.2.2.MRI Systems
11.2.2.2.3.Ultrasound Systems
11.2.2.2.4.Mammography Systems
11.2.2.2.5.Nuclear Imaging Systems
11.2.2.3.Biopsy Instruments
11.3.North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1.Breast Cancer
11.3.2.Colorectal Cancer
11.3.3.Cervical Cancer
11.3.4.Lung Cancer
11.3.5.Prostate Cancer
11.3.6.Skin Cancer
11.3.7.Blood Cancer
11.3.8.Kidney Cancer
11.3.9.Liver Cancer
11.3.10.Pancreatic Cancer
11.3.11.Others
11.4.North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.4.1.Hospitals
11.4.2.Diagnostic Laboratories
11.4.3.Research Institutes
11.4.4.Others
11.5.North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1.U.S
11.5.1.1.U.S Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
11.5.1.1.1.Consumables
11.5.1.1.1.1.Antibodies
11.5.1.1.1.2.Kits and Reagents
11.5.1.1.1.3.Probes
11.5.1.1.1.4.Other Consumables
11.5.1.1.2.Instruments
11.5.1.1.2.1.Pathology-Based Instruments
11.5.1.1.2.1.1.Slide Staining Systems
11.5.1.1.2.1.2.Tissue Processing Systems
11.5.1.1.2.1.3.NGS Instruments
11.5.1.1.2.1.4.Cell Processors
11.5.1.1.2.1.5.PCR Instruments
11.5.1.1.2.1.6.Microarrays
11.5.1.1.2.1.7.Other Pathology-Based Instruments
11.5.1.1.2.2.Imaging Instruments
11.5.1.1.2.2.1.CT Systems
11.5.1.1.2.2.2.MRI Systems
11.5.1.1.2.2.3.Ultrasound Systems
11.5.1.1.2.2.4.Mammography Systems
11.5.1.1.2.2.5.Nuclear Imaging Systems
11.5.1.1.2.3.Biopsy Instruments
11.5.1.2.U.S Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.2.1.Breast Cancer
11.5.1.2.2.Colorectal Cancer
11.5.1.2.3.Cervical Cancer
11.5.1.2.4.Lung Cancer
11.5.1.2.5.Prostate Cancer
11.5.1.2.6.Skin Cancer
11.5.1.2.7.Blood Cancer
11.5.1.2.8.Kidney Cancer
11.5.1.2.9.Liver Cancer
11.5.1.2.10.Pancreatic Cancer
11.5.1.2.11.Others
11.5.1.3.U.S Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.1.3.1.Hospitals
11.5.1.3.2.Diagnostic Laboratories
11.5.1.3.3.Research Institutes
11.5.1.3.4.Others
11.5.2.Canada
11.5.2.1.Canada Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
11.5.2.1.1.Consumables
11.5.2.1.1.1.Antibodies
11.5.2.1.1.2.Kits and Reagents
11.5.2.1.1.3.Probes
11.5.2.1.1.4.Other Consumables
11.5.2.1.2.Instruments
11.5.2.1.2.1.Pathology-Based Instruments
11.5.2.1.2.1.1.Slide Staining Systems
11.5.2.1.2.1.2.Tissue Processing Systems
11.5.2.1.2.1.3.NGS Instruments
11.5.2.1.2.1.4.Cell Processors
11.5.2.1.2.1.5.PCR Instruments
11.5.2.1.2.1.6.Microarrays
11.5.2.1.2.1.7.Other Pathology-Based Instruments
11.5.2.1.2.2.Imaging Instruments
11.5.2.1.2.2.1.CT Systems
11.5.2.1.2.2.2.MRI Systems
11.5.2.1.2.2.3.Ultrasound Systems
11.5.2.1.2.2.4.Mammography Systems
11.5.2.1.2.2.5.Nuclear Imaging Systems
11.5.2.1.2.3.Biopsy Instruments
11.5.2.2.Canada Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1.Breast Cancer
11.5.2.2.2.Colorectal Cancer
11.5.2.2.3.Cervical Cancer
11.5.2.2.4.Lung Cancer
11.5.2.2.5.Prostate Cancer
11.5.2.2.6.Skin Cancer
11.5.2.2.7.Blood Cancer
11.5.2.2.8.Kidney Cancer
11.5.2.2.9.Liver Cancer
11.5.2.2.10.Pancreatic Cancer
11.5.2.2.11.Others
11.5.2.3.Canada Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.2.3.1.Hospitals
11.5.2.3.2.Diagnostic Laboratories
11.5.2.3.3.Research Institutes
11.5.2.3.4.Others
11.5.3.Mexico
11.5.3.1.Mexico Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
11.5.3.1.1.Consumables
11.5.3.1.1.1.Antibodies
11.5.3.1.1.2.Kits and Reagents
11.5.3.1.1.3.Probes
11.5.3.1.1.4.Other Consumables
11.5.3.1.2.Instruments
11.5.3.1.2.1.Pathology-Based Instruments
11.5.3.1.2.1.1.Slide Staining Systems
11.5.3.1.2.1.2.Tissue Processing Systems
11.5.3.1.2.1.3.NGS Instruments
11.5.3.1.2.1.4.Cell Processors
11.5.3.1.2.1.5.PCR Instruments
11.5.3.1.2.1.6.Microarrays
11.5.3.1.2.1.7.Other Pathology-Based Instruments
11.5.3.1.2.2.Imaging Instruments
11.5.3.1.2.2.1.CT Systems
11.5.3.1.2.2.2.MRI Systems
11.5.3.1.2.2.3.Ultrasound Systems
11.5.3.1.2.2.4.Mammography Systems
11.5.3.1.2.2.5.Nuclear Imaging Systems
11.5.3.1.2.3.Biopsy Instruments
11.5.3.2.Mexico Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.2.1.Breast Cancer
11.5.3.2.2.Colorectal Cancer
11.5.3.2.3.Cervical Cancer
11.5.3.2.4.Lung Cancer
11.5.3.2.5.Prostate Cancer
11.5.3.2.6.Skin Cancer
11.5.3.2.7.Blood Cancer
11.5.3.2.8.Kidney Cancer
11.5.3.2.9.Liver Cancer
11.5.3.2.10.Pancreatic Cancer
11.5.3.2.11.Others
11.5.3.3.Mexico Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.3.3.1.Hospitals
11.5.3.3.2.Diagnostic Laboratories
11.5.3.3.3.Research Institutes
11.5.3.3.4.Others
11.5.4.Rest of North America
11.5.4.1.Rest of North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
11.5.4.1.1.Consumables
11.5.4.1.1.1.Antibodies
11.5.4.1.1.2.Kits and Reagents
11.5.4.1.1.3.Probes
11.5.4.1.1.4.Other Consumables
11.5.4.1.2.Instruments
11.5.4.1.2.1.Pathology-Based Instruments
11.5.4.1.2.1.1.Slide Staining Systems
11.5.4.1.2.1.2.Tissue Processing Systems
11.5.4.1.2.1.3.NGS Instruments
11.5.4.1.2.1.4.Cell Processors
11.5.4.1.2.1.5.PCR Instruments
11.5.4.1.2.1.6.Microarrays
11.5.4.1.2.1.7.Other Pathology-Based Instruments
11.5.4.1.2.2.Imaging Instruments
11.5.4.1.2.2.1.CT Systems
11.5.4.1.2.2.2.MRI Systems
11.5.4.1.2.2.3.Ultrasound Systems
11.5.4.1.2.2.4.Mammography Systems
11.5.4.1.2.2.5.Nuclear Imaging Systems
11.5.4.1.2.3.Biopsy Instruments
11.5.4.2.Rest of North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1.Breast Cancer
11.5.4.2.2.Colorectal Cancer
11.5.4.2.3.Cervical Cancer
11.5.4.2.4.Lung Cancer
11.5.4.2.5.Prostate Cancer
11.5.4.2.6.Skin Cancer
11.5.4.2.7.Blood Cancer
11.5.4.2.8.Kidney Cancer
11.5.4.2.9.Liver Cancer
11.5.4.2.10.Pancreatic Cancer
11.5.4.2.11.Others
11.5.4.3.Rest of North America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1.Hospitals
11.5.4.3.2.Diagnostic Laboratories
11.5.4.3.3.Research Institutes
11.5.4.3.4.Others
11.6.Key Segment for Channeling Investments
11.6.1.By Country
11.6.2.By Products
11.6.3.By Application
11.6.4.By End User
12.Europe Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
12.1.Overview
12.1.1.Europe Cancer Diagnostics Market Revenue (US$ Mn)
12.2.Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.2.1.Consumables
12.2.1.1.Antibodies
12.2.1.2.Kits and Reagents
12.2.1.3.Probes
12.2.1.4.Other Consumables
12.2.2.Instruments
12.2.2.1.Pathology-Based Instruments
12.2.2.1.1.Slide Staining Systems
12.2.2.1.2.Tissue Processing Systems
12.2.2.1.3.NGS Instruments
12.2.2.1.4.Cell Processors
12.2.2.1.5.PCR Instruments
12.2.2.1.6.Microarrays
12.2.2.1.7.Other Pathology-Based Instruments
12.2.2.2.Imaging Instruments
12.2.2.2.1.CT Systems
12.2.2.2.2.MRI Systems
12.2.2.2.3.Ultrasound Systems
12.2.2.2.4.Mammography Systems
12.2.2.2.5.Nuclear Imaging Systems
12.2.2.3.Biopsy Instruments
12.3.Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1.Breast Cancer
12.3.2.Colorectal Cancer
12.3.3.Cervical Cancer
12.3.4.Lung Cancer
12.3.5.Prostate Cancer
12.3.6.Skin Cancer
12.3.7.Blood Cancer
12.3.8.Kidney Cancer
12.3.9.Liver Cancer
12.3.10.Pancreatic Cancer
12.3.11.Others
12.4.Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.4.1.Hospitals
12.4.2.Diagnostic Laboratories
12.4.3.Research Institutes
12.4.4.Others
12.5.Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1.France
12.5.1.1.France Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.1.1.1.Consumables
12.5.1.1.1.1.Antibodies
12.5.1.1.1.2.Kits and Reagents
12.5.1.1.1.3.Probes
12.5.1.1.1.4.Other Consumables
12.5.1.1.2.Instruments
12.5.1.1.2.1.Pathology-Based Instruments
12.5.1.1.2.1.1.Slide Staining Systems
12.5.1.1.2.1.2.Tissue Processing Systems
12.5.1.1.2.1.3.NGS Instruments
12.5.1.1.2.1.4.Cell Processors
12.5.1.1.2.1.5.PCR Instruments
12.5.1.1.2.1.6.Microarrays
12.5.1.1.2.1.7.Other Pathology-Based Instruments
12.5.1.1.2.2.Imaging Instruments
12.5.1.1.2.2.1.CT Systems
12.5.1.1.2.2.2.MRI Systems
12.5.1.1.2.2.3.Ultrasound Systems
12.5.1.1.2.2.4.Mammography Systems
12.5.1.1.2.2.5.Nuclear Imaging Systems
12.5.1.1.2.3.Biopsy Instruments
12.5.1.2.France Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1.Breast Cancer
12.5.1.2.2.Colorectal Cancer
12.5.1.2.3.Cervical Cancer
12.5.1.2.4.Lung Cancer
12.5.1.2.5.Prostate Cancer
12.5.1.2.6.Skin Cancer
12.5.1.2.7.Blood Cancer
12.5.1.2.8.Kidney Cancer
12.5.1.2.9.Liver Cancer
12.5.1.2.10.Pancreatic Cancer
12.5.1.2.11.Others
12.5.1.3.France Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1.3.1.Hospitals
12.5.1.3.2.Diagnostic Laboratories
12.5.1.3.3.Research Institutes
12.5.1.3.4.Others
12.5.2.The UK
12.5.2.1.The UK Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.2.1.1.Consumables
12.5.2.1.1.1.Antibodies
12.5.2.1.1.2.Kits and Reagents
12.5.2.1.1.3.Probes
12.5.2.1.1.4.Other Consumables
12.5.2.1.2.Instruments
12.5.2.1.2.1.Pathology-Based Instruments
12.5.2.1.2.1.1.Slide Staining Systems
12.5.2.1.2.1.2.Tissue Processing Systems
12.5.2.1.2.1.3.NGS Instruments
12.5.2.1.2.1.4.Cell Processors
12.5.2.1.2.1.5.PCR Instruments
12.5.2.1.2.1.6.Microarrays
12.5.2.1.2.1.7.Other Pathology-Based Instruments
12.5.2.1.2.2.Imaging Instruments
12.5.2.1.2.2.1.CT Systems
12.5.2.1.2.2.2.MRI Systems
12.5.2.1.2.2.3.Ultrasound Systems
12.5.2.1.2.2.4.Mammography Systems
12.5.2.1.2.2.5.Nuclear Imaging Systems
12.5.2.1.2.3.Biopsy Instruments
12.5.2.2.The UK Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.2.1.Breast Cancer
12.5.2.2.2.Colorectal Cancer
12.5.2.2.3.Cervical Cancer
12.5.2.2.4.Lung Cancer
12.5.2.2.5.Prostate Cancer
12.5.2.2.6.Skin Cancer
12.5.2.2.7.Blood Cancer
12.5.2.2.8.Kidney Cancer
12.5.2.2.9.Liver Cancer
12.5.2.2.10.Pancreatic Cancer
12.5.2.2.11.Others
12.5.2.3.The UK Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.2.3.1.Hospitals
12.5.2.3.2.Diagnostic Laboratories
12.5.2.3.3.Research Institutes
12.5.2.3.4.Others
12.5.3.Spain
12.5.3.1.Spain Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.3.1.1.Consumables
12.5.3.1.1.1.Antibodies
12.5.3.1.1.2.Kits and Reagents
12.5.3.1.1.3.Probes
12.5.3.1.1.4.Other Consumables
12.5.3.1.2.Instruments
12.5.3.1.2.1.Pathology-Based Instruments
12.5.3.1.2.1.1.Slide Staining Systems
12.5.3.1.2.1.2.Tissue Processing Systems
12.5.3.1.2.1.3.NGS Instruments
12.5.3.1.2.1.4.Cell Processors
12.5.3.1.2.1.5.PCR Instruments
12.5.3.1.2.1.6.Microarrays
12.5.3.1.2.1.7.Other Pathology-Based Instruments
12.5.3.1.2.2.Imaging Instruments
12.5.3.1.2.2.1.CT Systems
12.5.3.1.2.2.2.MRI Systems
12.5.3.1.2.2.3.Ultrasound Systems
12.5.3.1.2.2.4.Mammography Systems
12.5.3.1.2.2.5.Nuclear Imaging Systems
12.5.3.1.2.3.Biopsy Instruments
12.5.3.2.Spain Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1.Breast Cancer
12.5.3.2.2.Colorectal Cancer
12.5.3.2.3.Cervical Cancer
12.5.3.2.4.Lung Cancer
12.5.3.2.5.Prostate Cancer
12.5.3.2.6.Skin Cancer
12.5.3.2.7.Blood Cancer
12.5.3.2.8.Kidney Cancer
12.5.3.2.9.Liver Cancer
12.5.3.2.10.Pancreatic Cancer
12.5.3.2.11.Others
12.5.3.3.Spain Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.3.3.1.Hospitals
12.5.3.3.2.Diagnostic Laboratories
12.5.3.3.3.Research Institutes
12.5.3.3.4.Others
12.5.4.Germany
12.5.4.1.Germany Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.4.1.1.Consumables
12.5.4.1.1.1.Antibodies
12.5.4.1.1.2.Kits and Reagents
12.5.4.1.1.3.Probes
12.5.4.1.1.4.Other Consumables
12.5.4.1.2.Instruments
12.5.4.1.2.1.Pathology-Based Instruments
12.5.4.1.2.1.1.Slide Staining Systems
12.5.4.1.2.1.2.Tissue Processing Systems
12.5.4.1.2.1.3.NGS Instruments
12.5.4.1.2.1.4.Cell Processors
12.5.4.1.2.1.5.PCR Instruments
12.5.4.1.2.1.6.Microarrays
12.5.4.1.2.1.7.Other Pathology-Based Instruments
12.5.4.1.2.2.Imaging Instruments
12.5.4.1.2.2.1.CT Systems
12.5.4.1.2.2.2.MRI Systems
12.5.4.1.2.2.3.Ultrasound Systems
12.5.4.1.2.2.4.Mammography Systems
12.5.4.1.2.2.5.Nuclear Imaging Systems
12.5.4.1.2.3.Biopsy Instruments
12.5.4.2.Germany Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1.Breast Cancer
12.5.4.2.2.Colorectal Cancer
12.5.4.2.3.Cervical Cancer
12.5.4.2.4.Lung Cancer
12.5.4.2.5.Prostate Cancer
12.5.4.2.6.Skin Cancer
12.5.4.2.7.Blood Cancer
12.5.4.2.8.Kidney Cancer
12.5.4.2.9.Liver Cancer
12.5.4.2.10.Pancreatic Cancer
12.5.4.2.11.Others
12.5.4.3.Germany Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.4.3.1.Hospitals
12.5.4.3.2.Diagnostic Laboratories
12.5.4.3.3.Research Institutes
12.5.4.3.4.Others
12.5.5.Italy
12.5.5.1.Italy Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.5.1.1.Consumables
12.5.5.1.1.1.Antibodies
12.5.5.1.1.2.Kits and Reagents
12.5.5.1.1.3.Probes
12.5.5.1.1.4.Other Consumables
12.5.5.1.2.Instruments
12.5.5.1.2.1.Pathology-Based Instruments
12.5.5.1.2.1.1.Slide Staining Systems
12.5.5.1.2.1.2.Tissue Processing Systems
12.5.5.1.2.1.3.NGS Instruments
12.5.5.1.2.1.4.Cell Processors
12.5.5.1.2.1.5.PCR Instruments
12.5.5.1.2.1.6.Microarrays
12.5.5.1.2.1.7.Other Pathology-Based Instruments
12.5.5.1.2.2.Imaging Instruments
12.5.5.1.2.2.1.CT Systems
12.5.5.1.2.2.2.MRI Systems
12.5.5.1.2.2.3.Ultrasound Systems
12.5.5.1.2.2.4.Mammography Systems
12.5.5.1.2.2.5.Nuclear Imaging Systems
12.5.5.1.2.3.Biopsy Instruments
12.5.5.2.Italy Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.2.1.Breast Cancer
12.5.5.2.2.Colorectal Cancer
12.5.5.2.3.Cervical Cancer
12.5.5.2.4.Lung Cancer
12.5.5.2.5.Prostate Cancer
12.5.5.2.6.Skin Cancer
12.5.5.2.7.Blood Cancer
12.5.5.2.8.Kidney Cancer
12.5.5.2.9.Liver Cancer
12.5.5.2.10.Pancreatic Cancer
12.5.5.2.11.Others
12.5.5.3.Italy Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.5.3.1.Hospitals
12.5.5.3.2.Diagnostic Laboratories
12.5.5.3.3.Research Institutes
12.5.5.3.4.Others
12.5.6.Nordic Countries
12.5.6.1.Nordic Countries Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.6.1.1.Consumables
12.5.6.1.1.1.Antibodies
12.5.6.1.1.2.Kits and Reagents
12.5.6.1.1.3.Probes
12.5.6.1.1.4.Other Consumables
12.5.6.1.2.Instruments
12.5.6.1.2.1.Pathology-Based Instruments
12.5.6.1.2.1.1.Slide Staining Systems
12.5.6.1.2.1.2.Tissue Processing Systems
12.5.6.1.2.1.3.NGS Instruments
12.5.6.1.2.1.4.Cell Processors
12.5.6.1.2.1.5.PCR Instruments
12.5.6.1.2.1.6.Microarrays
12.5.6.1.2.1.7.Other Pathology-Based Instruments
12.5.6.1.2.2.Imaging Instruments
12.5.6.1.2.2.1.CT Systems
12.5.6.1.2.2.2.MRI Systems
12.5.6.1.2.2.3.Ultrasound Systems
12.5.6.1.2.2.4.Mammography Systems
12.5.6.1.2.2.5.Nuclear Imaging Systems
12.5.6.1.2.3.Biopsy Instruments
12.5.6.2.Nordic Countries Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.2.1.Breast Cancer
12.5.6.2.2.Colorectal Cancer
12.5.6.2.3.Cervical Cancer
12.5.6.2.4.Lung Cancer
12.5.6.2.5.Prostate Cancer
12.5.6.2.6.Skin Cancer
12.5.6.2.7.Blood Cancer
12.5.6.2.8.Kidney Cancer
12.5.6.2.9.Liver Cancer
12.5.6.2.10.Pancreatic Cancer
12.5.6.2.11.Others
12.5.6.3.Nordic Countries Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1.Hospitals
12.5.6.3.2.Diagnostic Laboratories
12.5.6.3.3.Research Institutes
12.5.6.3.4.Others
12.5.6.4.Nordic Countries Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.Denmark
12.5.6.4.2.Finland
12.5.6.4.3.Iceland
12.5.6.4.4.Sweden
12.5.6.4.5.Norway
12.5.7.Benelux Union
12.5.7.1.Benelux Union Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.7.1.1.Consumables
12.5.7.1.1.1.Antibodies
12.5.7.1.1.2.Kits and Reagents
12.5.7.1.1.3.Probes
12.5.7.1.1.4.Other Consumables
12.5.7.1.2.Instruments
12.5.7.1.2.1.Pathology-Based Instruments
12.5.7.1.2.1.1.Slide Staining Systems
12.5.7.1.2.1.2.Tissue Processing Systems
12.5.7.1.2.1.3.NGS Instruments
12.5.7.1.2.1.4.Cell Processors
12.5.7.1.2.1.5.PCR Instruments
12.5.7.1.2.1.6.Microarrays
12.5.7.1.2.1.7.Other Pathology-Based Instruments
12.5.7.1.2.2.Imaging Instruments
12.5.7.1.2.2.1.CT Systems
12.5.7.1.2.2.2.MRI Systems
12.5.7.1.2.2.3.Ultrasound Systems
12.5.7.1.2.2.4.Mammography Systems
12.5.7.1.2.2.5.Nuclear Imaging Systems
12.5.7.1.2.3.Biopsy Instruments
12.5.7.2.Benelux Union Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1.Breast Cancer
12.5.7.2.2.Colorectal Cancer
12.5.7.2.3.Cervical Cancer
12.5.7.2.4.Lung Cancer
12.5.7.2.5.Prostate Cancer
12.5.7.2.6.Skin Cancer
12.5.7.2.7.Blood Cancer
12.5.7.2.8.Kidney Cancer
12.5.7.2.9.Liver Cancer
12.5.7.2.10.Pancreatic Cancer
12.5.7.2.11.Others
12.5.7.3.Benelux Union Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1.Hospitals
12.5.7.3.2.Diagnostic Laboratories
12.5.7.3.3.Research Institutes
12.5.7.3.4.Others
12.5.7.4.Benelux Union Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.Belgium
12.5.7.4.2.The Netherlands
12.5.7.4.3.Luxembourg
12.5.8.Rest of Europe
12.5.8.1.Rest of Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
12.5.8.1.1.Consumables
12.5.8.1.1.1.Antibodies
12.5.8.1.1.2.Kits and Reagents
12.5.8.1.1.3.Probes
12.5.8.1.1.4.Other Consumables
12.5.8.1.2.Instruments
12.5.8.1.2.1.Pathology-Based Instruments
12.5.8.1.2.1.1.Slide Staining Systems
12.5.8.1.2.1.2.Tissue Processing Systems
12.5.8.1.2.1.3.NGS Instruments
12.5.8.1.2.1.4.Cell Processors
12.5.8.1.2.1.5.PCR Instruments
12.5.8.1.2.1.6.Microarrays
12.5.8.1.2.1.7.Other Pathology-Based Instruments
12.5.8.1.2.2.Imaging Instruments
12.5.8.1.2.2.1.CT Systems
12.5.8.1.2.2.2.MRI Systems
12.5.8.1.2.2.3.Ultrasound Systems
12.5.8.1.2.2.4.Mammography Systems
12.5.8.1.2.2.5.Nuclear Imaging Systems
12.5.8.1.2.3.Biopsy Instruments
12.5.8.2.Rest of Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.2.1.Breast Cancer
12.5.8.2.2.Colorectal Cancer
12.5.8.2.3.Cervical Cancer
12.5.8.2.4.Lung Cancer
12.5.8.2.5.Prostate Cancer
12.5.8.2.6.Skin Cancer
12.5.8.2.7.Blood Cancer
12.5.8.2.8.Kidney Cancer
12.5.8.2.9.Liver Cancer
12.5.8.2.10.Pancreatic Cancer
12.5.8.2.11.Others
12.5.8.3.Rest of Europe Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.8.3.1.Hospitals
12.5.8.3.2.Diagnostic Laboratories
12.5.8.3.3.Research Institutes
12.5.8.3.4.Others
12.6.Key Segment for Channeling Investments
12.6.1.By Country
12.6.2.By Products
12.6.3.By Application
12.6.4.By End User
13.Asia Pacific Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
13.1.Overview
13.1.1.Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn)
13.2.Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.2.1.Consumables
13.2.1.1.Antibodies
13.2.1.2.Kits and Reagents
13.2.1.3.Probes
13.2.1.4.Other Consumables
13.2.2.Instruments
13.2.2.1.Pathology-Based Instruments
13.2.2.1.1.Slide Staining Systems
13.2.2.1.2.Tissue Processing Systems
13.2.2.1.3.NGS Instruments
13.2.2.1.4.Cell Processors
13.2.2.1.5.PCR Instruments
13.2.2.1.6.Microarrays
13.2.2.1.7.Other Pathology-Based Instruments
13.2.2.2.Imaging Instruments
13.2.2.2.1.CT Systems
13.2.2.2.2.MRI Systems
13.2.2.2.3.Ultrasound Systems
13.2.2.2.4.Mammography Systems
13.2.2.2.5.Nuclear Imaging Systems
13.2.2.3.Biopsy Instruments
13.3.Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1.Breast Cancer
13.3.2.Colorectal Cancer
13.3.3.Cervical Cancer
13.3.4.Lung Cancer
13.3.5.Prostate Cancer
13.3.6.Skin Cancer
13.3.7.Blood Cancer
13.3.8.Kidney Cancer
13.3.9.Liver Cancer
13.3.10.Pancreatic Cancer
13.3.11.Others
13.4.Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.4.1.Hospitals
13.4.2.Diagnostic Laboratories
13.4.3.Research Institutes
13.4.4.Others
13.5.Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1.China
13.5.1.1.China Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.1.1.1.Consumables
13.5.1.1.1.1.Antibodies
13.5.1.1.1.2.Kits and Reagents
13.5.1.1.1.3.Probes
13.5.1.1.1.4.Other Consumables
13.5.1.1.2.Instruments
13.5.1.1.2.1.Pathology-Based Instruments
13.5.1.1.2.1.1.Slide Staining Systems
13.5.1.1.2.1.2.Tissue Processing Systems
13.5.1.1.2.1.3.NGS Instruments
13.5.1.1.2.1.4.Cell Processors
13.5.1.1.2.1.5.PCR Instruments
13.5.1.1.2.1.6.Microarrays
13.5.1.1.2.1.7.Other Pathology-Based Instruments
13.5.1.1.2.2.Imaging Instruments
13.5.1.1.2.2.1.CT Systems
13.5.1.1.2.2.2.MRI Systems
13.5.1.1.2.2.3.Ultrasound Systems
13.5.1.1.2.2.4.Mammography Systems
13.5.1.1.2.2.5.Nuclear Imaging Systems
13.5.1.1.2.3.Biopsy Instruments
13.5.1.2.China Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.2.1.Breast Cancer
13.5.1.2.2.Colorectal Cancer
13.5.1.2.3.Cervical Cancer
13.5.1.2.4.Lung Cancer
13.5.1.2.5.Prostate Cancer
13.5.1.2.6.Skin Cancer
13.5.1.2.7.Blood Cancer
13.5.1.2.8.Kidney Cancer
13.5.1.2.9.Liver Cancer
13.5.1.2.10.Pancreatic Cancer
13.5.1.2.11.Others
13.5.1.3.China Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1.3.1.Hospitals
13.5.1.3.2.Diagnostic Laboratories
13.5.1.3.3.Research Institutes
13.5.1.3.4.Others
13.5.2.Japan
13.5.2.1.Japan Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.2.1.1.Consumables
13.5.2.1.1.1.Antibodies
13.5.2.1.1.2.Kits and Reagents
13.5.2.1.1.3.Probes
13.5.2.1.1.4.Other Consumables
13.5.2.1.2.Instruments
13.5.2.1.2.1.Pathology-Based Instruments
13.5.2.1.2.1.1.Slide Staining Systems
13.5.2.1.2.1.2.Tissue Processing Systems
13.5.2.1.2.1.3.NGS Instruments
13.5.2.1.2.1.4.Cell Processors
13.5.2.1.2.1.5.PCR Instruments
13.5.2.1.2.1.6.Microarrays
13.5.2.1.2.1.7.Other Pathology-Based Instruments
13.5.2.1.2.2.Imaging Instruments
13.5.2.1.2.2.1.CT Systems
13.5.2.1.2.2.2.MRI Systems
13.5.2.1.2.2.3.Ultrasound Systems
13.5.2.1.2.2.4.Mammography Systems
13.5.2.1.2.2.5.Nuclear Imaging Systems
13.5.2.1.2.3.Biopsy Instruments
13.5.2.2.Japan Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.2.1.Breast Cancer
13.5.2.2.2.Colorectal Cancer
13.5.2.2.3.Cervical Cancer
13.5.2.2.4.Lung Cancer
13.5.2.2.5.Prostate Cancer
13.5.2.2.6.Skin Cancer
13.5.2.2.7.Blood Cancer
13.5.2.2.8.Kidney Cancer
13.5.2.2.9.Liver Cancer
13.5.2.2.10.Pancreatic Cancer
13.5.2.2.11.Others
13.5.2.3.Japan Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.2.3.1.Hospitals
13.5.2.3.2.Diagnostic Laboratories
13.5.2.3.3.Research Institutes
13.5.2.3.4.Others
13.5.3.India
13.5.3.1.India Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.3.1.1.Consumables
13.5.3.1.1.1.Antibodies
13.5.3.1.1.2.Kits and Reagents
13.5.3.1.1.3.Probes
13.5.3.1.1.4.Other Consumables
13.5.3.1.2.Instruments
13.5.3.1.2.1.Pathology-Based Instruments
13.5.3.1.2.1.1.Slide Staining Systems
13.5.3.1.2.1.2.Tissue Processing Systems
13.5.3.1.2.1.3.NGS Instruments
13.5.3.1.2.1.4.Cell Processors
13.5.3.1.2.1.5.PCR Instruments
13.5.3.1.2.1.6.Microarrays
13.5.3.1.2.1.7.Other Pathology-Based Instruments
13.5.3.1.2.2.Imaging Instruments
13.5.3.1.2.2.1.CT Systems
13.5.3.1.2.2.2.MRI Systems
13.5.3.1.2.2.3.Ultrasound Systems
13.5.3.1.2.2.4.Mammography Systems
13.5.3.1.2.2.5.Nuclear Imaging Systems
13.5.3.1.2.3.Biopsy Instruments
13.5.3.2.India Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1.Breast Cancer
13.5.3.2.2.Colorectal Cancer
13.5.3.2.3.Cervical Cancer
13.5.3.2.4.Lung Cancer
13.5.3.2.5.Prostate Cancer
13.5.3.2.6.Skin Cancer
13.5.3.2.7.Blood Cancer
13.5.3.2.8.Kidney Cancer
13.5.3.2.9.Liver Cancer
13.5.3.2.10.Pancreatic Cancer
13.5.3.2.11.Others
13.5.3.3.India Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.3.3.1.Hospitals
13.5.3.3.2.Diagnostic Laboratories
13.5.3.3.3.Research Institutes
13.5.3.3.4.Others
13.5.4.New Zealand
13.5.4.1.New Zealand Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.4.1.1.Consumables
13.5.4.1.1.1.Antibodies
13.5.4.1.1.2.Kits and Reagents
13.5.4.1.1.3.Probes
13.5.4.1.1.4.Other Consumables
13.5.4.1.2.Instruments
13.5.4.1.2.1.Pathology-Based Instruments
13.5.4.1.2.1.1.Slide Staining Systems
13.5.4.1.2.1.2.Tissue Processing Systems
13.5.4.1.2.1.3.NGS Instruments
13.5.4.1.2.1.4.Cell Processors
13.5.4.1.2.1.5.PCR Instruments
13.5.4.1.2.1.6.Microarrays
13.5.4.1.2.1.7.Other Pathology-Based Instruments
13.5.4.1.2.2.Imaging Instruments
13.5.4.1.2.2.1.CT Systems
13.5.4.1.2.2.2.MRI Systems
13.5.4.1.2.2.3.Ultrasound Systems
13.5.4.1.2.2.4.Mammography Systems
13.5.4.1.2.2.5.Nuclear Imaging Systems
13.5.4.1.2.3.Biopsy Instruments
13.5.4.2.New Zealand Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.2.1.Breast Cancer
13.5.4.2.2.Colorectal Cancer
13.5.4.2.3.Cervical Cancer
13.5.4.2.4.Lung Cancer
13.5.4.2.5.Prostate Cancer
13.5.4.2.6.Skin Cancer
13.5.4.2.7.Blood Cancer
13.5.4.2.8.Kidney Cancer
13.5.4.2.9.Liver Cancer
13.5.4.2.10.Pancreatic Cancer
13.5.4.2.11.Others
13.5.4.3.New Zealand Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1.Hospitals
13.5.4.3.2.Diagnostic Laboratories
13.5.4.3.3.Research Institutes
13.5.4.3.4.Others
13.5.5.Australia
13.5.5.1.Australia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.5.1.1.Consumables
13.5.5.1.1.1.Antibodies
13.5.5.1.1.2.Kits and Reagents
13.5.5.1.1.3.Probes
13.5.5.1.1.4.Other Consumables
13.5.5.1.2.Instruments
13.5.5.1.2.1.Pathology-Based Instruments
13.5.5.1.2.1.1.Slide Staining Systems
13.5.5.1.2.1.2.Tissue Processing Systems
13.5.5.1.2.1.3.NGS Instruments
13.5.5.1.2.1.4.Cell Processors
13.5.5.1.2.1.5.PCR Instruments
13.5.5.1.2.1.6.Microarrays
13.5.5.1.2.1.7.Other Pathology-Based Instruments
13.5.5.1.2.2.Imaging Instruments
13.5.5.1.2.2.1.CT Systems
13.5.5.1.2.2.2.MRI Systems
13.5.5.1.2.2.3.Ultrasound Systems
13.5.5.1.2.2.4.Mammography Systems
13.5.5.1.2.2.5.Nuclear Imaging Systems
13.5.5.1.2.3.Biopsy Instruments
13.5.5.2.Australia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1.Breast Cancer
13.5.5.2.2.Colorectal Cancer
13.5.5.2.3.Cervical Cancer
13.5.5.2.4.Lung Cancer
13.5.5.2.5.Prostate Cancer
13.5.5.2.6.Skin Cancer
13.5.5.2.7.Blood Cancer
13.5.5.2.8.Kidney Cancer
13.5.5.2.9.Liver Cancer
13.5.5.2.10.Pancreatic Cancer
13.5.5.2.11.Others
13.5.5.3.Australia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1.Hospitals
13.5.5.3.2.Diagnostic Laboratories
13.5.5.3.3.Research Institutes
13.5.5.3.4.Others
13.5.6.South Korea
13.5.6.1.South Korea Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.6.1.1.Consumables
13.5.6.1.1.1.Antibodies
13.5.6.1.1.2.Kits and Reagents
13.5.6.1.1.3.Probes
13.5.6.1.1.4.Other Consumables
13.5.6.1.2.Instruments
13.5.6.1.2.1.Pathology-Based Instruments
13.5.6.1.2.1.1.Slide Staining Systems
13.5.6.1.2.1.2.Tissue Processing Systems
13.5.6.1.2.1.3.NGS Instruments
13.5.6.1.2.1.4.Cell Processors
13.5.6.1.2.1.5.PCR Instruments
13.5.6.1.2.1.6.Microarrays
13.5.6.1.2.1.7.Other Pathology-Based Instruments
13.5.6.1.2.2.Imaging Instruments
13.5.6.1.2.2.1.CT Systems
13.5.6.1.2.2.2.MRI Systems
13.5.6.1.2.2.3.Ultrasound Systems
13.5.6.1.2.2.4.Mammography Systems
13.5.6.1.2.2.5.Nuclear Imaging Systems
13.5.6.1.2.3.Biopsy Instruments
13.5.6.2.South Korea Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.2.1.Breast Cancer
13.5.6.2.2.Colorectal Cancer
13.5.6.2.3.Cervical Cancer
13.5.6.2.4.Lung Cancer
13.5.6.2.5.Prostate Cancer
13.5.6.2.6.Skin Cancer
13.5.6.2.7.Blood Cancer
13.5.6.2.8.Kidney Cancer
13.5.6.2.9.Liver Cancer
13.5.6.2.10.Pancreatic Cancer
13.5.6.2.11.Others
13.5.6.3.South Korea Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.6.3.1.Hospitals
13.5.6.3.2.Diagnostic Laboratories
13.5.6.3.3.Research Institutes
13.5.6.3.4.Others
13.5.7.Southeast Asia
13.5.7.1.Southeast Asia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.7.1.1.Consumables
13.5.7.1.1.1.Antibodies
13.5.7.1.1.2.Kits and Reagents
13.5.7.1.1.3.Probes
13.5.7.1.1.4.Other Consumables
13.5.7.1.2.Instruments
13.5.7.1.2.1.Pathology-Based Instruments
13.5.7.1.2.1.1.Slide Staining Systems
13.5.7.1.2.1.2.Tissue Processing Systems
13.5.7.1.2.1.3.NGS Instruments
13.5.7.1.2.1.4.Cell Processors
13.5.7.1.2.1.5.PCR Instruments
13.5.7.1.2.1.6.Microarrays
13.5.7.1.2.1.7.Other Pathology-Based Instruments
13.5.7.1.2.2.Imaging Instruments
13.5.7.1.2.2.1.CT Systems
13.5.7.1.2.2.2.MRI Systems
13.5.7.1.2.2.3.Ultrasound Systems
13.5.7.1.2.2.4.Mammography Systems
13.5.7.1.2.2.5.Nuclear Imaging Systems
13.5.7.1.2.3.Biopsy Instruments
13.5.7.2.Southeast Asia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1.Breast Cancer
13.5.7.2.2.Colorectal Cancer
13.5.7.2.3.Cervical Cancer
13.5.7.2.4.Lung Cancer
13.5.7.2.5.Prostate Cancer
13.5.7.2.6.Skin Cancer
13.5.7.2.7.Blood Cancer
13.5.7.2.8.Kidney Cancer
13.5.7.2.9.Liver Cancer
13.5.7.2.10.Pancreatic Cancer
13.5.7.2.11.Others
13.5.7.3.Southeast Asia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1.Hospitals
13.5.7.3.2.Diagnostic Laboratories
13.5.7.3.3.Research Institutes
13.5.7.3.4.Others
13.5.7.4.Southeast Asia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.Indonesia
13.5.7.4.2.Thailand
13.5.7.4.3.Malaysia
13.5.7.4.4.Singapore
13.5.7.4.5.Rest of Southeast Asia
13.5.8.Rest of Asia Pacific
13.5.8.1.Rest of Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
13.5.8.1.1.Consumables
13.5.8.1.1.1.Antibodies
13.5.8.1.1.2.Kits and Reagents
13.5.8.1.1.3.Probes
13.5.8.1.1.4.Other Consumables
13.5.8.1.2.Instruments
13.5.8.1.2.1.Pathology-Based Instruments
13.5.8.1.2.1.1.Slide Staining Systems
13.5.8.1.2.1.2.Tissue Processing Systems
13.5.8.1.2.1.3.NGS Instruments
13.5.8.1.2.1.4.Cell Processors
13.5.8.1.2.1.5.PCR Instruments
13.5.8.1.2.1.6.Microarrays
13.5.8.1.2.1.7.Other Pathology-Based Instruments
13.5.8.1.2.2.Imaging Instruments
13.5.8.1.2.2.1.CT Systems
13.5.8.1.2.2.2.MRI Systems
13.5.8.1.2.2.3.Ultrasound Systems
13.5.8.1.2.2.4.Mammography Systems
13.5.8.1.2.2.5.Nuclear Imaging Systems
13.5.8.1.2.3.Biopsy Instruments
13.5.8.2.Rest of Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1.Breast Cancer
13.5.8.2.2.Colorectal Cancer
13.5.8.2.3.Cervical Cancer
13.5.8.2.4.Lung Cancer
13.5.8.2.5.Prostate Cancer
13.5.8.2.6.Skin Cancer
13.5.8.2.7.Blood Cancer
13.5.8.2.8.Kidney Cancer
13.5.8.2.9.Liver Cancer
13.5.8.2.10.Pancreatic Cancer
13.5.8.2.11.Others
13.5.8.3.Rest of Asia Pacific Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1.Hospitals
13.5.8.3.2.Diagnostic Laboratories
13.5.8.3.3.Research Institutes
13.5.8.3.4.Others
13.6.Key Segment for Channeling Investments
13.6.1.By Country
13.6.2.By Products
13.6.3.By Application
13.6.4.By End User
14.Middle East and Africa Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
14.1.Overview
14.1.1.Middle East and Africa Cancer Diagnostics Market Revenue (US$ Mn)
14.2.Middle East and Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.2.1.Consumables
14.2.1.1.Antibodies
14.2.1.2.Kits and Reagents
14.2.1.3.Probes
14.2.1.4.Other Consumables
14.2.2.Instruments
14.2.2.1.Pathology-Based Instruments
14.2.2.1.1.Slide Staining Systems
14.2.2.1.2.Tissue Processing Systems
14.2.2.1.3.NGS Instruments
14.2.2.1.4.Cell Processors
14.2.2.1.5.PCR Instruments
14.2.2.1.6.Microarrays
14.2.2.1.7.Other Pathology-Based Instruments
14.2.2.2.Imaging Instruments
14.2.2.2.1.CT Systems
14.2.2.2.2.MRI Systems
14.2.2.2.3.Ultrasound Systems
14.2.2.2.4.Mammography Systems
14.2.2.2.5.Nuclear Imaging Systems
14.2.2.3.Biopsy Instruments
14.3.Middle East and Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1.Breast Cancer
14.3.2.Colorectal Cancer
14.3.3.Cervical Cancer
14.3.4.Lung Cancer
14.3.5.Prostate Cancer
14.3.6.Skin Cancer
14.3.7.Blood Cancer
14.3.8.Kidney Cancer
14.3.9.Liver Cancer
14.3.10.Pancreatic Cancer
14.3.11.Others
14.4.Middle East and Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1.Hospitals
14.4.2.Diagnostic Laboratories
14.4.3.Research Institutes
14.4.4.Others
14.5.Middle East and Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1.Saudi Arabia
14.5.1.1.Saudi Arabia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.1.1.1.Consumables
14.5.1.1.1.1.Antibodies
14.5.1.1.1.2.Kits and Reagents
14.5.1.1.1.3.Probes
14.5.1.1.1.4.Other Consumables
14.5.1.1.2.Instruments
14.5.1.1.2.1.Pathology-Based Instruments
14.5.1.1.2.1.1.Slide Staining Systems
14.5.1.1.2.1.2.Tissue Processing Systems
14.5.1.1.2.1.3.NGS Instruments
14.5.1.1.2.1.4.Cell Processors
14.5.1.1.2.1.5.PCR Instruments
14.5.1.1.2.1.6.Microarrays
14.5.1.1.2.1.7.Other Pathology-Based Instruments
14.5.1.1.2.2.Imaging Instruments
14.5.1.1.2.2.1.CT Systems
14.5.1.1.2.2.2.MRI Systems
14.5.1.1.2.2.3.Ultrasound Systems
14.5.1.1.2.2.4.Mammography Systems
14.5.1.1.2.2.5.Nuclear Imaging Systems
14.5.1.1.2.3.Biopsy Instruments
14.5.1.2.Saudi Arabia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.2.1.Breast Cancer
14.5.1.2.2.Colorectal Cancer
14.5.1.2.3.Cervical Cancer
14.5.1.2.4.Lung Cancer
14.5.1.2.5.Prostate Cancer
14.5.1.2.6.Skin Cancer
14.5.1.2.7.Blood Cancer
14.5.1.2.8.Kidney Cancer
14.5.1.2.9.Liver Cancer
14.5.1.2.10.Pancreatic Cancer
14.5.1.2.11.Others
14.5.1.3.Saudi Arabia Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1.Hospitals
14.5.1.3.2.Diagnostic Laboratories
14.5.1.3.3.Research Institutes
14.5.1.3.4.Others
14.5.2.UAE
14.5.2.1.UAE Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.2.1.1.Consumables
14.5.2.1.1.1.Antibodies
14.5.2.1.1.2.Kits and Reagents
14.5.2.1.1.3.Probes
14.5.2.1.1.4.Other Consumables
14.5.2.1.2.Instruments
14.5.2.1.2.1.Pathology-Based Instruments
14.5.2.1.2.1.1.Slide Staining Systems
14.5.2.1.2.1.2.Tissue Processing Systems
14.5.2.1.2.1.3.NGS Instruments
14.5.2.1.2.1.4.Cell Processors
14.5.2.1.2.1.5.PCR Instruments
14.5.2.1.2.1.6.Microarrays
14.5.2.1.2.1.7.Other Pathology-Based Instruments
14.5.2.1.2.2.Imaging Instruments
14.5.2.1.2.2.1.CT Systems
14.5.2.1.2.2.2.MRI Systems
14.5.2.1.2.2.3.Ultrasound Systems
14.5.2.1.2.2.4.Mammography Systems
14.5.2.1.2.2.5.Nuclear Imaging Systems
14.5.2.1.2.3.Biopsy Instruments
14.5.2.2.UAE Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.2.1.Breast Cancer
14.5.2.2.2.Colorectal Cancer
14.5.2.2.3.Cervical Cancer
14.5.2.2.4.Lung Cancer
14.5.2.2.5.Prostate Cancer
14.5.2.2.6.Skin Cancer
14.5.2.2.7.Blood Cancer
14.5.2.2.8.Kidney Cancer
14.5.2.2.9.Liver Cancer
14.5.2.2.10.Pancreatic Cancer
14.5.2.2.11.Others
14.5.2.3.UAE Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.2.3.1.Hospitals
14.5.2.3.2.Diagnostic Laboratories
14.5.2.3.3.Research Institutes
14.5.2.3.4.Others
14.5.3.Egypt
14.5.3.1.Egypt Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.3.1.1.Consumables
14.5.3.1.1.1.Antibodies
14.5.3.1.1.2.Kits and Reagents
14.5.3.1.1.3.Probes
14.5.3.1.1.4.Other Consumables
14.5.3.1.2.Instruments
14.5.3.1.2.1.Pathology-Based Instruments
14.5.3.1.2.1.1.Slide Staining Systems
14.5.3.1.2.1.2.Tissue Processing Systems
14.5.3.1.2.1.3.NGS Instruments
14.5.3.1.2.1.4.Cell Processors
14.5.3.1.2.1.5.PCR Instruments
14.5.3.1.2.1.6.Microarrays
14.5.3.1.2.1.7.Other Pathology-Based Instruments
14.5.3.1.2.2.Imaging Instruments
14.5.3.1.2.2.1.CT Systems
14.5.3.1.2.2.2.MRI Systems
14.5.3.1.2.2.3.Ultrasound Systems
14.5.3.1.2.2.4.Mammography Systems
14.5.3.1.2.2.5.Nuclear Imaging Systems
14.5.3.1.2.3.Biopsy Instruments
14.5.3.2.Egypt Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1.Breast Cancer
14.5.3.2.2.Colorectal Cancer
14.5.3.2.3.Cervical Cancer
14.5.3.2.4.Lung Cancer
14.5.3.2.5.Prostate Cancer
14.5.3.2.6.Skin Cancer
14.5.3.2.7.Blood Cancer
14.5.3.2.8.Kidney Cancer
14.5.3.2.9.Liver Cancer
14.5.3.2.10.Pancreatic Cancer
14.5.3.2.11.Others
14.5.3.3.Egypt Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.3.3.1.Hospitals
14.5.3.3.2.Diagnostic Laboratories
14.5.3.3.3.Research Institutes
14.5.3.3.4.Others
14.5.4.Kuwait
14.5.4.1.Kuwait Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.4.1.1.Consumables
14.5.4.1.1.1.Antibodies
14.5.4.1.1.2.Kits and Reagents
14.5.4.1.1.3.Probes
14.5.4.1.1.4.Other Consumables
14.5.4.1.2.Instruments
14.5.4.1.2.1.Pathology-Based Instruments
14.5.4.1.2.1.1.Slide Staining Systems
14.5.4.1.2.1.2.Tissue Processing Systems
14.5.4.1.2.1.3.NGS Instruments
14.5.4.1.2.1.4.Cell Processors
14.5.4.1.2.1.5.PCR Instruments
14.5.4.1.2.1.6.Microarrays
14.5.4.1.2.1.7.Other Pathology-Based Instruments
14.5.4.1.2.2.Imaging Instruments
14.5.4.1.2.2.1.CT Systems
14.5.4.1.2.2.2.MRI Systems
14.5.4.1.2.2.3.Ultrasound Systems
14.5.4.1.2.2.4.Mammography Systems
14.5.4.1.2.2.5.Nuclear Imaging Systems
14.5.4.1.2.3.Biopsy Instruments
14.5.4.2.Kuwait Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1.Breast Cancer
14.5.4.2.2.Colorectal Cancer
14.5.4.2.3.Cervical Cancer
14.5.4.2.4.Lung Cancer
14.5.4.2.5.Prostate Cancer
14.5.4.2.6.Skin Cancer
14.5.4.2.7.Blood Cancer
14.5.4.2.8.Kidney Cancer
14.5.4.2.9.Liver Cancer
14.5.4.2.10.Pancreatic Cancer
14.5.4.2.11.Others
14.5.4.3.Kuwait Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.4.3.1.Hospitals
14.5.4.3.2.Diagnostic Laboratories
14.5.4.3.3.Research Institutes
14.5.4.3.4.Others
14.5.5.South Africa
14.5.5.1.South Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.5.1.1.Consumables
14.5.5.1.1.1.Antibodies
14.5.5.1.1.2.Kits and Reagents
14.5.5.1.1.3.Probes
14.5.5.1.1.4.Other Consumables
14.5.5.1.2.Instruments
14.5.5.1.2.1.Pathology-Based Instruments
14.5.5.1.2.1.1.Slide Staining Systems
14.5.5.1.2.1.2.Tissue Processing Systems
14.5.5.1.2.1.3.NGS Instruments
14.5.5.1.2.1.4.Cell Processors
14.5.5.1.2.1.5.PCR Instruments
14.5.5.1.2.1.6.Microarrays
14.5.5.1.2.1.7.Other Pathology-Based Instruments
14.5.5.1.2.2.Imaging Instruments
14.5.5.1.2.2.1.CT Systems
14.5.5.1.2.2.2.MRI Systems
14.5.5.1.2.2.3.Ultrasound Systems
14.5.5.1.2.2.4.Mammography Systems
14.5.5.1.2.2.5.Nuclear Imaging Systems
14.5.5.1.2.3.Biopsy Instruments
14.5.5.2.South Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.2.1.Breast Cancer
14.5.5.2.2.Colorectal Cancer
14.5.5.2.3.Cervical Cancer
14.5.5.2.4.Lung Cancer
14.5.5.2.5.Prostate Cancer
14.5.5.2.6.Skin Cancer
14.5.5.2.7.Blood Cancer
14.5.5.2.8.Kidney Cancer
14.5.5.2.9.Liver Cancer
14.5.5.2.10.Pancreatic Cancer
14.5.5.2.11.Others
14.5.5.3.South Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.5.3.1.Hospitals
14.5.5.3.2.Diagnostic Laboratories
14.5.5.3.3.Research Institutes
14.5.5.3.4.Others
14.5.6.Rest of Middle East & Africa
14.5.6.1.Rest of Middle East & Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
14.5.6.1.1.Consumables
14.5.6.1.1.1.Antibodies
14.5.6.1.1.2.Kits and Reagents
14.5.6.1.1.3.Probes
14.5.6.1.1.4.Other Consumables
14.5.6.1.2.Instruments
14.5.6.1.2.1.Pathology-Based Instruments
14.5.6.1.2.1.1.Slide Staining Systems
14.5.6.1.2.1.2.Tissue Processing Systems
14.5.6.1.2.1.3.NGS Instruments
14.5.6.1.2.1.4.Cell Processors
14.5.6.1.2.1.5.PCR Instruments
14.5.6.1.2.1.6.Microarrays
14.5.6.1.2.1.7.Other Pathology-Based Instruments
14.5.6.1.2.2.Imaging Instruments
14.5.6.1.2.2.1.CT Systems
14.5.6.1.2.2.2.MRI Systems
14.5.6.1.2.2.3.Ultrasound Systems
14.5.6.1.2.2.4.Mammography Systems
14.5.6.1.2.2.5.Nuclear Imaging Systems
14.5.6.1.2.3.Biopsy Instruments
14.5.6.2.Rest of Middle East & Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1.Breast Cancer
14.5.6.2.2.Colorectal Cancer
14.5.6.2.3.Cervical Cancer
14.5.6.2.4.Lung Cancer
14.5.6.2.5.Prostate Cancer
14.5.6.2.6.Skin Cancer
14.5.6.2.7.Blood Cancer
14.5.6.2.8.Kidney Cancer
14.5.6.2.9.Liver Cancer
14.5.6.2.10.Pancreatic Cancer
14.5.6.2.11.Others
14.5.6.3.Rest of Middle East & Africa Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1.Hospitals
14.5.6.3.2.Diagnostic Laboratories
14.5.6.3.3.Research Institutes
14.5.6.3.4.Others
14.6.Key Segment for Channeling Investments
14.6.1.By Country
14.6.2.By Products
14.6.3.By Application
14.6.4.By End User
15.Latin America Cancer Diagnostics Market Analysis and Forecasts, 2023 - 2031
15.1.Overview
15.1.1.Latin America Cancer Diagnostics Market Revenue (US$ Mn)
15.2.Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
15.2.1.Consumables
15.2.1.1.Antibodies
15.2.1.2.Kits and Reagents
15.2.1.3.Probes
15.2.1.4.Other Consumables
15.2.2.Instruments
15.2.2.1.Pathology-Based Instruments
15.2.2.1.1.Slide Staining Systems
15.2.2.1.2.Tissue Processing Systems
15.2.2.1.3.NGS Instruments
15.2.2.1.4.Cell Processors
15.2.2.1.5.PCR Instruments
15.2.2.1.6.Microarrays
15.2.2.1.7.Other Pathology-Based Instruments
15.2.2.2.Imaging Instruments
15.2.2.2.1.CT Systems
15.2.2.2.2.MRI Systems
15.2.2.2.3.Ultrasound Systems
15.2.2.2.4.Mammography Systems
15.2.2.2.5.Nuclear Imaging Systems
15.2.2.3.Biopsy Instruments
15.3.Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1.Breast Cancer
15.3.2.Colorectal Cancer
15.3.3.Cervical Cancer
15.3.4.Lung Cancer
15.3.5.Prostate Cancer
15.3.6.Skin Cancer
15.3.7.Blood Cancer
15.3.8.Kidney Cancer
15.3.9.Liver Cancer
15.3.10.Pancreatic Cancer
15.3.11.Others
15.4.Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.4.1.Hospitals
15.4.2.Diagnostic Laboratories
15.4.3.Research Institutes
15.4.4.Others
15.5.Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1.Brazil
15.5.1.1.Brazil Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
15.5.1.1.1.Consumables
15.5.1.1.1.1.Antibodies
15.5.1.1.1.2.Kits and Reagents
15.5.1.1.1.3.Probes
15.5.1.1.1.4.Other Consumables
15.5.1.1.2.Instruments
15.5.1.1.2.1.Pathology-Based Instruments
15.5.1.1.2.1.1.Slide Staining Systems
15.5.1.1.2.1.2.Tissue Processing Systems
15.5.1.1.2.1.3.NGS Instruments
15.5.1.1.2.1.4.Cell Processors
15.5.1.1.2.1.5.PCR Instruments
15.5.1.1.2.1.6.Microarrays
15.5.1.1.2.1.7.Other Pathology-Based Instruments
15.5.1.1.2.2.Imaging Instruments
15.5.1.1.2.2.1.CT Systems
15.5.1.1.2.2.2.MRI Systems
15.5.1.1.2.2.3.Ultrasound Systems
15.5.1.1.2.2.4.Mammography Systems
15.5.1.1.2.2.5.Nuclear Imaging Systems
15.5.1.1.2.3.Biopsy Instruments
15.5.1.2.Brazil Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1.Breast Cancer
15.5.1.2.2.Colorectal Cancer
15.5.1.2.3.Cervical Cancer
15.5.1.2.4.Lung Cancer
15.5.1.2.5.Prostate Cancer
15.5.1.2.6.Skin Cancer
15.5.1.2.7.Blood Cancer
15.5.1.2.8.Kidney Cancer
15.5.1.2.9.Liver Cancer
15.5.1.2.10.Pancreatic Cancer
15.5.1.2.11.Others
15.5.1.3.Brazil Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1.3.1.Hospitals
15.5.1.3.2.Diagnostic Laboratories
15.5.1.3.3.Research Institutes
15.5.1.3.4.Others
15.5.2.Argentina
15.5.2.1.Argentina Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
15.5.2.1.1.Consumables
15.5.2.1.1.1.Antibodies
15.5.2.1.1.2.Kits and Reagents
15.5.2.1.1.3.Probes
15.5.2.1.1.4.Other Consumables
15.5.2.1.2.Instruments
15.5.2.1.2.1.Pathology-Based Instruments
15.5.2.1.2.1.1.Slide Staining Systems
15.5.2.1.2.1.2.Tissue Processing Systems
15.5.2.1.2.1.3.NGS Instruments
15.5.2.1.2.1.4.Cell Processors
15.5.2.1.2.1.5.PCR Instruments
15.5.2.1.2.1.6.Microarrays
15.5.2.1.2.1.7.Other Pathology-Based Instruments
15.5.2.1.2.2.Imaging Instruments
15.5.2.1.2.2.1.CT Systems
15.5.2.1.2.2.2.MRI Systems
15.5.2.1.2.2.3.Ultrasound Systems
15.5.2.1.2.2.4.Mammography Systems
15.5.2.1.2.2.5.Nuclear Imaging Systems
15.5.2.1.2.3.Biopsy Instruments
15.5.2.2.Argentina Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.2.1.Breast Cancer
15.5.2.2.2.Colorectal Cancer
15.5.2.2.3.Cervical Cancer
15.5.2.2.4.Lung Cancer
15.5.2.2.5.Prostate Cancer
15.5.2.2.6.Skin Cancer
15.5.2.2.7.Blood Cancer
15.5.2.2.8.Kidney Cancer
15.5.2.2.9.Liver Cancer
15.5.2.2.10.Pancreatic Cancer
15.5.2.2.11.Others
15.5.2.3.Argentina Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.2.3.1.Hospitals
15.5.2.3.2.Diagnostic Laboratories
15.5.2.3.3.Research Institutes
15.5.2.3.4.Others
15.5.3.Rest of Latin America
15.5.3.1.Rest of Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
15.5.3.1.1.Consumables
15.5.3.1.1.1.Antibodies
15.5.3.1.1.2.Kits and Reagents
15.5.3.1.1.3.Probes
15.5.3.1.1.4.Other Consumables
15.5.3.1.2.Instruments
15.5.3.1.2.1.Pathology-Based Instruments
15.5.3.1.2.1.1.Slide Staining Systems
15.5.3.1.2.1.2.Tissue Processing Systems
15.5.3.1.2.1.3.NGS Instruments
15.5.3.1.2.1.4.Cell Processors
15.5.3.1.2.1.5.PCR Instruments
15.5.3.1.2.1.6.Microarrays
15.5.3.1.2.1.7.Other Pathology-Based Instruments
15.5.3.1.2.2.Imaging Instruments
15.5.3.1.2.2.1.CT Systems
15.5.3.1.2.2.2.MRI Systems
15.5.3.1.2.2.3.Ultrasound Systems
15.5.3.1.2.2.4.Mammography Systems
15.5.3.1.2.2.5.Nuclear Imaging Systems
15.5.3.1.2.3.Biopsy Instruments
15.5.3.2.Rest of Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.2.1.Breast Cancer
15.5.3.2.2.Colorectal Cancer
15.5.3.2.3.Cervical Cancer
15.5.3.2.4.Lung Cancer
15.5.3.2.5.Prostate Cancer
15.5.3.2.6.Skin Cancer
15.5.3.2.7.Blood Cancer
15.5.3.2.8.Kidney Cancer
15.5.3.2.9.Liver Cancer
15.5.3.2.10.Pancreatic Cancer
15.5.3.2.11.Others
15.5.3.3.Rest of Latin America Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1.Hospitals
15.5.3.3.2.Diagnostic Laboratories
15.5.3.3.3.Research Institutes
15.5.3.3.4.Others
15.6.Key Segment for Channeling Investments
15.6.1.By Country
15.6.2.By Products
15.6.3.By Application
15.6.4.By End User
16.Competitive Benchmarking
16.1.Brand Benchmarking
16.2.Market Share Analysis, 2022
16.3.Global Presence and Growth Strategies
16.3.1.Mergers and Acquisitions
16.3.2.Product Launches
16.3.3.Investments Trends
16.3.4.R&D Initiatives
17.Player Profiles
17.1.Abbott
17.1.1.Company Details
17.1.2.Company Overview
17.1.3.Product Offerings
17.1.4.Key Developments
17.1.5.Financial Analysis
17.1.6.SWOT Analysis
17.1.7.Business Strategies
17.2.BD
17.2.1.Company Details
17.2.2.Company Overview
17.2.3.Product Offerings
17.2.4.Key Developments
17.2.5.Financial Analysis
17.2.6.SWOT Analysis
17.2.7.Business Strategies
17.3.Bio-Rad Laboratories, Inc.
17.3.1.Company Details
17.3.2.Company Overview
17.3.3.Product Offerings
17.3.4.Key Developments
17.3.5.Financial Analysis
17.3.6.SWOT Analysis
17.3.7.Business Strategies
17.4.F. Hoffmann-La Roche Ltd
17.4.1.Company Details
17.4.2.Company Overview
17.4.3.Product Offerings
17.4.4.Key Developments
17.4.5.Financial Analysis
17.4.6.SWOT Analysis
17.4.7.Business Strategies
17.5.GE HealthCare
17.5.1.Company Details
17.5.2.Company Overview
17.5.3.Product Offerings
17.5.4.Key Developments
17.5.5.Financial Analysis
17.5.6.SWOT Analysis
17.5.7.Business Strategies
17.6.Hologic, Inc.
17.6.1.Company Details
17.6.2.Company Overview
17.6.3.Product Offerings
17.6.4.Key Developments
17.6.5.Financial Analysis
17.6.6.SWOT Analysis
17.6.7.Business Strategies
17.7.Koninklijke Philips N.V.
17.7.1.Company Details
17.7.2.Company Overview
17.7.3.Product Offerings
17.7.4.Key Developments
17.7.5.Financial Analysis
17.7.6.SWOT Analysis
17.7.7.Business Strategies
17.8.QIAGEN
17.8.1.Company Details
17.8.2.Company Overview
17.8.3.Product Offerings
17.8.4.Key Developments
17.8.5.Financial Analysis
17.8.6.SWOT Analysis
17.8.7.Business Strategies
17.9.Siemens Healthcare GmbH
17.9.1.Company Details
17.9.2.Company Overview
17.9.3.Product Offerings
17.9.4.Key Developments
17.9.5.Financial Analysis
17.9.6.SWOT Analysis
17.9.7.Business Strategies
17.10.Thermo Fisher Scientific Inc.
17.10.1.Company Details
17.10.2.Company Overview
17.10.3.Product Offerings
17.10.4.Key Developments
17.10.5.Financial Analysis
17.10.6.SWOT Analysis
17.10.7.Business Strategies
17.11.Other Market Participants
18.Key Findings

.

**Exclusive for Multi-User and Enterprise User.

Global Cancer Diagnostics Market Segmentation

By Product

 Consumables
 Antibodies
 Kits & Reagents
 Probes
 Other Consumables
 Instruments